R. Hetman

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

J. Berlin, H. Lenz, J. Marshall, 2018, British Journal of Cancer.

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

P. Ansell, J. Gietema, M. D. de Jonge, 2018, Investigational New Drugs.

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

P. Ansell, J. Gietema, Diane A van der Biessen, 2018, Investigational New Drugs.

Pilot study of veliparib (ABT-888) with temozolomide (TMZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

V. Giranda, M. Carducci, M. Hussain, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pilot study of veliparib (ABT-888) with temozolomide (TMZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

V. Giranda, M. Carducci, M. Hussain, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.

J. Berlin, H. Lenz, V. Giranda, 2014 .